Opinion

Published within

« | ... | 1565 | 1566 | 1567 | 1568 | 1569 | 1570 | 1571 | 1572 | 1573 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Bayer/GSK: time is money in erectile dysfunction

Trial data suggests that Bayer [BAY.F]/GSK's [GSK.L] erectile dysfunction drug Levitra becomes effective within ten minutes. This reinforces the perception that Levitra may prove the best provider of an on-demand antidote to erectile dysfunction.

Published By Datamonitor
12 May 2004
CommentWire
CommentWire

Bayer/GSK: Levitra approved by FDA

The success of the erectile dysfunction drug Levitra is crucial for Bayer's [BAY.F] short-term future, as the company has little else in the pipeline to provide growth potential. For GSK [GSK.L], although less vital for survival, the success of this drug launch is also of key importance.

Published By Datamonitor
20 Aug 2003
CommentWire
CommentWire

Bayer/CuraGen: billion-dollar genomics alliance

Published By Datamonitor
19 Jan 2001
CommentWire
CommentWire

Bayer/Aventis: growth opportunities with CropScience

Published By Datamonitor
10 Jul 2001
CommentWire
CommentWire

Bayer/Aventis: a healthy crop business

Published By Datamonitor
02 Oct 2001
CommentWire
CommentWire

Bayer Schering/Onyx: Nexavar suffers setback in lung cancer

Disappointing Phase III data presents a considerable blow to Nexavar's prospects of expansion into the potentially lucrative indication of non-small-cell lung cancer. While development of the drug is likely to continue in this indication, the negative trial results and inevitable delay to market could prove costly.

Published By Datamonitor
20 Feb 2008
CommentWire
CommentWire

Bayer and Titan: Spheramine cell therapy discontinued

Bayer has discontinued development of Spheramine due to a failed Phase IIb trial. Spheramine is a cell-based therapy in which human retinal cells are injected into the brain, producing levodopa, which is then converted to dopamine. While this is disappointing for the development of a cell-based therapy for Parkinson's disease, a number of gene therapies in development offer hope for sufferers.

Published By Datamonitor
04 Jul 2008
Expert View
Expert View

Baycol: Bayer back from the brink?

Bayer AG has gained a much needed boost after a jury cleared the company of liability in a $560 million lawsuit case involving the cholesterol medication Baycol. With the German pharmaceuticals group involved in a further 8,000 lawsuits this first ruling has suggested that the company may not be facing compensation payouts of $10 billion as initially feared.<BR />

Published By Datamonitor
18 Apr 2003
CommentWire
CommentWire

Baxters: making luxury a priority in the soup category

Baxters has announced plans to relaunch its entire soup line in the UK, adding new recipes and changing the labeling to enhance the brand's premium positioning. This is a smart move, given the soup category's strong growth potential in the recessionary period and the high consumer demand for low-priced, quality foods.

Published By Datamonitor
19 Aug 2009
CommentWire
CommentWire

Baxter: under fire over contaminated heparin

Already the subject of criticism over the withdrawal of its Chinese-made blood thinner heparin, Baxter International has now been accused of failing to co-operate with Chinese authorities trying to investigate the alleged contamination. The fallout of this saga could yet hold implications for other drug makers looking to gain benefit from low cost manufacturing countries such as China.

Published By Datamonitor
07 May 2008

« | ... | 1565 | 1566 | 1567 | 1568 | 1569 | 1570 | 1571 | 1572 | 1573 | ... | » »|

No help is available.